地域外来医・専門医のための心不全診療実践マニュアル

出版社： メディカ出版
著者：
発行日： 2021-02-20
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784840475105
電子書籍版： 2021-02-20 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

11,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

11,000 円(税込)

購入する

商品紹介

心不全診療に特効薬はない。心エコー学、放射線学、薬理学、症候学、大規模臨床研究、ガイドライン・政策、分子生物学、数理科学・AIを駆使した全方向からのアプローチが必要だ。心不全診療に精通し、首尾一貫した戦略をとる著者による、診療歴40年の経験と知恵が詰まった1冊。

目次

  • 【I章　心不全とは】
    1. はじめに
    2. 心不全の定義と疫学
    3. 心不全の分類
    4. 心不全は心血行動態の障害から始まる
    5. 心不全は心ポンプ機能低下の問題でない？
    臨床に役立てる俯瞰の目
    ＜Column＞ β遮断薬の検討

    【II章　患者から見た心不全診療】
    1. 大動脈弁狭窄症
    2. 急性左心不全
    3. 高血圧性心不全
    4. 拘束型心筋症
    5. 急性心筋炎
    6. 頻脈誘発性心筋症（tachycardia-induced cardiomyopathy）
    7. 高血圧性心筋症または肥大型心筋症拡張相
    8. 珍しい三尖弁閉鎖不全症
    ＜Column＞ 大切なメッセージ
    9. 高齢者の心不全診療
    　〔急性心不全〕
    　〔慢性心不全〕
    10. 心不全の緩和医療
    ＜Column＞ kick the bucket
    臨床に役立てる俯瞰の目

    【III章　個別の心血管疾患から見た心不全診療】
    1. 大動脈弁狭窄症（aortic stenosis：AS)
    2. 大動脈弁逆流症（aortic regurgitation：AR）
    3. 僧帽弁狭窄症（mitral stenosis：MS）
    4. 僧帽弁逆流症（mitral regurgitation：MR）
    5. 三尖弁逆流症（tricuspid regurgitation：TR）
    6. 拡張型心筋症（dilated cardiomyopathy：DCM）
    ＜Column＞ APOLLO試験
    7. 肥大型心筋症（hypertrophic cardiomyopathy：HCM）
    8. 二次性心筋症
    ＜Column＞ ミトコンドリア心筋症
    9. 高血圧性心不全（hypertensive heart disease：HHD）
    10. 虚血性心疾患
    臨床に役立てる俯瞰の目

    【IV章　実臨床から見た心不全診療】
    1. 臨床的観点から見た心不全とは
    2. 急性心不全とは
    3. 急性心不全の成因・誘因
    4. 急性心不全の病態
    5. 急性心不全の治療
    6. 慢性心不全とは
    ＜Column＞ 心不全患者さんの水分摂取
    7. 慢性心不全の治療
    臨床に役立てる俯瞰の目

    【V章　他臓器疾患から見た心不全診療】
    1. 腎機能障害
    2. 糖尿病
    3. 高血圧
    4. 慢性閉塞性肺疾患（COPD）
    5. 貧血
    6. がん
    7. フレイル・サルコペニア
    臨床に役立てる俯瞰の目

    【VI章　薬理学から見た心不全診療】
    1. 急性心不全の治療薬
    2. 急性心不全の治療薬をいかに組み合わせて治療するか？
    3. 慢性心不全の内服薬治療
    臨床に役立てる俯瞰の目

    【VII章　心不全の歴史から見た心不全診療―温故知新】
    1. 心不全学の歴史
    2. 20世紀前半までの心不全の考え方
    3. 20世紀後半の心不全の考え方
    ＜Column＞ ラプラスの法則を心臓に応用する？
    4. 心不全治療の考えに心臓力学を取り入れたことの功罪
    5. ジギタリスの位置づけ
    6. 心不全への新しい考え方―神経体液因子の概念の導入
    ＜Column＞ ネガティブデータも論文に
    7. 心不全治療への新しい考え方―心臓移植と補助循環そして心筋細胞・遺伝子療法

    【VIII章　心臓生理学から見た心不全診療】
    1. 心臓の働き
    2. 筋細胞における心筋収縮のメカニズム
    3. 心筋収縮とCa★2＋★－生化学的観点
    ＜Column＞ 新たな知的創造に不可欠なCa★2＋★シグナル
    4. 心筋収縮・弛緩の生理学
    5. 心室収縮の生理学
    6. 心室弛緩の生理学
    7. 心臓生理学から見た心不全
    臨床に役立てる俯瞰の目

    【IX章　システム生理学から見た心不全診療】
    1. 心臓を中心としたシステム生理学
    2. システム生理学から見たHFrEFとHFpEF
    ＜Column＞ 心臓から拍出された血液が心臓に影響を及ぼす理由
    3. システム生理学から見た低拍出性心不全と高拍出性心不全
    4. 神経調節から見たシステム生理学
    臨床に役立てる俯瞰の目

    【X章　大規模臨床研究から見た心不全診療】
    1. 臨床研究とは何か？
    2. 臨床研究で何を知りたいか？
    3. 心不全治療におけるACE阻害薬
    4. 心不全治療におけるアンジオテンシンII受容体拮抗薬
    　　　（angiotensin II receptor blocker：ARB）
    5. ACE阻害薬とARBの違い
    6. 心不全治療におけるMRA（mineralocorticoid receptor antagonist）
    7. 心不全治療におけるβ遮断薬
    8. 心不全治療におけるカルペリチドとネシリチド
    ＜Column＞ カルペリチドの添付文書
    9. 心不全治療におけるサクビトリルバルサルタンナトリウム水和物
    10. 心不全治療におけるSGLT2阻害薬
    11. 心不全治療におけるスタチン
    12. 心不全治療におけるトルバプタンの有用性
    13. 心不全治療におけるその他の薬物治療の有用性
    14. 心不全治療における心臓再同期療法
    15. 心不全治療における心臓移植と補助循環
    16. 心不全治療における観察研究からの成果
    臨床に役立てる俯瞰の目

    【XI章　ガイドラインから見た心不全診療】
    1. 急性心不全と慢性心不全を一本化
    2. エビデンスのレベル
    3. 心不全診断のフローチャート
    4. 心不全治療のフローチャート
    臨床に役立てる俯瞰の目

    【XII章　循環器5カ年計画から見た心不全診療】
    1. 心不全の疫学とそのトレンド
    2. 心不全病態把握の問題点
    3. 心不全治療の問題点
    4. 心不全予防の問題点
    5. 急性心不全における救急医療体制にかかわる問題点
    6. 慢性心不全にかかわる医療体制の問題点
    7. 心不全にかかわる研究の問題点
    8. 心不全克服５カ年計画の理念と目標
    ＜Column＞ 心不全にかかわる事業とその裏方たち

    【XIII章　分子生物学・ゲノム医学から見た心不全診療】
    1. 最低限知っておきたい心筋細胞内シグナル伝達機能
    2. 不全心における分子生物学的調節
    3. 心筋疾患に見られる遺伝子異常
    4. 心筋疾患に見られる遺伝子発現異常
    臨床に役立てる俯瞰の目

    【XIV章　数理科学から見た心不全診療】
    1. 心不全症例の予後のスコア化
    2. 心不全症例の予後の数式化
    3. 心不全症例の予後数式化の実際
    ＜Column＞ データの集め方
    4. 心不全症例予後の数式化から見えてくる心不全医療のピットホール
    5. 血漿中BNPレベルから見た心不全症例予後の数式化
    臨床に役立てる俯瞰の目

    【XV章　ビッグデータ・AIから見た心不全診療】
    1. データ中心科学へ至る道
    2. データマイニングの考え方
    3. 心不全におけるデータマイニング
    臨床に役立てる俯瞰の目

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

引用・参考文献

P.354 掲載の参考文献
1) Poole-Wilson P. History, definition and classification of heart failure. Heart failure. 1997 ; 1 : 269-277.
 
2) 北風政史. 1. 心不全は心臓の病気か? 日本内科学会雑誌. 2014 ; 103 : 681-6.
 
3) Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP and et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. The New England journal of medicine. 1993 ; 329 : 149-55.
 
4) Yusuf S, Pitt B, Davis CE, Hood WB and Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The New England journal of medicine. 1991 ; 325 : 293-302.
PubMed
5) Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D and Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure : randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (London, England). 2000 ; 355 : 1582-7.
 
6) Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau J-L, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F and White H. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine. 2003 ; 349 : 1893-1906.
 
7) Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine. 1999 ; 341 : 709-17.
PubMed
8) Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ and Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine. 2011 ; 364 : 11-21.
PubMed
9) Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J and Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine. 2003 ; 348 : 1309-21.
PubMed
10) Waagstein F, Hjalmarson A, Varnauskas E and Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. British heart journal. 1975 ; 37 : 1022-36.
PubMed
11) Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM and Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. The New England journal of medicine. 1996 ; 334 : 1349-55.
 
12) A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994 ; 90 : 1765-73.
PubMed
13) 山田健二, 森本紳一郎, 平光伸也, 植村晃久, 久保奈津子, 木村勝智, 菱田仁 and 水野康. 臨床 拡張型心筋症における β 遮断薬療法の有用性, 適応と作用機序について. 心臓. 1993 ; 25 : 525-34.
 
14) Sharma G and Goodwin J. Effect of aging on respiratory system physiology and immunology. Clinical interventions in aging. 2006 ; 1 : 253-60.
PubMed
15) Weber M and Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart (British Cardiac Society). 2006 ; 92 : 843-9.
PubMed
16) Mebazaa A, Gheorghiade M, Pina IL, Harjola VP, Hollenberg SM, Follath F, Rhodes A, Plaisance P, Roland E, Nieminen M, Komajda M, Parkhomenko A, Masip J, Zannad F and Filippatos G. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008 ; 36 : S129-39.
PubMed
17) Kinugawa K, Inomata T, Sato N, Yasuda M, Shimakawa T, Bando K and Mizuguchi K. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study). Int Heart J. 2015 ; 56 : 137-43.
PubMed
18) Coleridge Smith PD, Hasty JH and Scurr JH. Deep vein thrombosis : effect of graduated compression stockings on distension of the deep veins of the calf. Br J Surg. 1991 ; 78 : 724-6.
PubMed
19) Rochon PA, Tu JV, Anderson GM, Gurwitz JH, Clark JP, Lau P, Szalai JP, Sykora K and Naylor CD. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet (London, England). 2000 ; 356 : 639-44.
 
20) Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC, Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL and Riegel B. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation : endorsed by the Heart Rhythm Society. Circulation. 2005 ; 112 : e154-235.
 
21) Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D and Turner MB. Heart disease and stroke statistics--2012 update : a report from the American Heart Association. Circulation. 2012 ; 125 : e2-e220.
PubMed
22) 河野博芳, 神代尚芳 and 井上 正. 完成期医療福祉システム・ネットワークづくり. 社会・経済システム. 1993 ; 12 : 1-12.
 
23) Allen LA, Yager JE, Funk MJ, Levy WC, Tulsky JA, Bowers MT, Dodson GC, O'Connor CM and Felker GM. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. Jama. 2008 ; 299 : 2533-42.
PubMed
24) Bonow RO, Carabello BA, Kanu C, de Leon AC, Jr., Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith SC, Jr., Jacobs AK, Adams CD, Anderson JL, Antman EM, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Page RL and Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) : developed in collaboration with the Society of Cardiovascular Anesthesiologists : endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006 ; 114 : e84-231.
 
25) Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L and Wenink A. Guidelines on the management of valvular heart disease : The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007 ; 28 : 230-68.
 
26) Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, Kraft CD, Miyake-Hull CY and Schwaegler RG. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation. 1997 ; 95 : 2262-70.
PubMed
27) Lancellotti P, Lebois F, Simon M, Tombeux C, Chauvel C and Pierard LA. Prognostic importance of quantitative exercise Doppler echocardiography in asymptomatic valvular aortic stenosis. Circulation. 2005 ; 112 : I377-82.
PubMed
28) Marechaux S, Ennezat PV, LeJemtel TH, Polge AS, de Groote P, Asseman P, Neviere R, Le Tourneau T and Deklunder G. Left ventricular response to exercise in aortic stenosis : an exercise echocardiographic study. Echocardiography. 2007 ; 24 : 955-9.
PubMed
29) Grayburn PA. Assessment of low-gradient aortic stenosis with dobutamine. Circulation. 2006 ; 113 : 604-6.
PubMed
30) Nishimura RA, Grantham JA, Connolly HM, Schaff HV, Higano ST and Holmes DR, Jr. Low-output, low-gradient aortic stenosis in patients with depressed left ventricular systolic function : the clinical utility of the dobutamine challenge in the catheterization laboratory. Circulation. 2002 ; 106 : 809-13.
PubMed
31) Monin JL, Monchi M, Gest V, Duval-Moulin AM, Dubois-Rande JL and Gueret P. Aortic stenosis with severe left ventricular dysfunction and low transvalvular pressure gradients : risk stratification by low-dose dobutamine echocardiography. J Am Coll Cardiol. 2001 ; 37 : 2101-7.
PubMed
32) Monin JL, Quere JP, Monchi M, Petit H, Baleynaud S, Chauvel C, Pop C, Ohlmann P, Lelguen C, Dehant P, Tribouilloy C and Gueret P. Low-gradient aortic stenosis : operative risk stratification and predictors for long-term outcome : a multicenter study using dobutamine stress hemodynamics. Circulation. 2003 ; 108 : 319-24.
PubMed
33) Schwammenthal E, Vered Z, Moshkowitz Y, Rabinowitz B, Ziskind Z, Smolinski AK and Feinberg MS. Dobutamine echocardiography in patients with aortic stenosis and left ventricular dysfunction : predicting outcome as a function of management strategy. Chest. 2001 ; 119 : 1766-77.
PubMed
34) deFilippi CR, Willett DL, Brickner ME, Appleton CP, Yancy CW, Eichhorn EJ and Grayburn PA. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low transvalvular gradients. Am J Cardiol. 1995 ; 75 : 191-4.
PubMed
35) Cannon JD, Jr., Zile MR, Crawford FA, Jr. and Carabello BA. Aortic valve resistance as an adjunct to the Gorlin formula in assessing the severity of aortic stenosis in symptomatic patients. J Am Coll Cardiol. 1992 ; 20 : 1517-23.
 
36) Blais C, Burwash IG, Mundigler G, Dumesnil JG, Loho N, Rader F, Baumgartner H, Beanlands RS, Chayer B, Kadem L, Garcia D, Durand LG and Pibarot P. Projected valve area at normal flow rate improves the assessment of stenosis severity in patients with low-flow, low-gradient aortic stenosis : the multicenter TOPAS (Truly or Pseudo-Severe Aortic Stenosis) study. Circulation. 2006 ; 113 : 711-21.
PubMed
37) Clavel M-A, Ennezat PV, Marechaux S, Dumesnil JG, Capoulade R, Hachicha Z, Mathieu P, Bellouin A, Bergeron S and Meimoun P. Stress echocardiography to assess stenosis severity and predict outcome in patients with paradoxical low-flow, low-gradient aortic stenosis and preserved LVEF. JACC : Cardiovascular Imaging. 2013 ; 6 : 175-183.
PubMed
38) Bountioukos M, Kertai MD, Schinkel AF, Vourvouri EC, Rizzello V, Krenning BJ, Bax JJ, Roelandt JR and Poldermans D. Safety of dobutamine stress echocardiography in patients with aortic stenosis. J Heart Valve Dis. 2003 ; 12 : 441-6.
PubMed
39) Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB and Tajik AJ. Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation. 1999 ; 99 : 1851-7.
PubMed
40) Wahi S, Haluska B, Pasquet A, Case C, Rimmerman CM and Marwick TH. Exercise echocardiography predicts development of left ventricular dysfunction in medically and surgically treated patients with asymptomatic severe aortic regurgitation. Heart. 2000 ; 84 : 606-14.
PubMed
41) Tunick PA, Freedberg RS, Gargiulo A and Kronzon I. Exercise Doppler echocardiography as an aid to clinical decision making in mitral valve disease. J Am Soc Echocardiogr. 1992 ; 5 : 225-30.
 
42) Reis G, Motta MS, Barbosa MM, Esteves WA, Souza SF and Bocchi EA. Dobutamine stress echocardiography for noninvasive assessment and risk stratification of patients with rheumatic mitral stenosis. J Am Coll Cardiol. 2004 ; 43 : 393-401.
PubMed
43) Schwammenthal E, Vered Z, Agranat O, Kaplinsky E, Rabinowitz B and Feinberg MS. Impact of atrioventricular compliance on pulmonary artery pressure in mitral stenosis : an exercise echocardiographic study. Circulation. 2000 ; 102 : 2378-84.
PubMed
44) Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, Scott C, Schaff HV and Tajik AJ. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. 2005 ; 352 : 875-83.
PubMed
45) Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M, Maurer G and Baumgartner H. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation. 2006 ; 113 : 2238-44.
PubMed
46) Kang DH, Kim JH, Rim JH, Kim MJ, Yun SC, Song JM, Song H, Choi KJ, Song JK and Lee JW. Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation. Circulation. 2009 ; 119 : 797-804.
 
47) Supino PG, Borer JS, Schuleri K, Gupta A, Hochreiter C, Kligfield P, Herrold EM and Preibisz JJ. Prognostic value of exercise tolerance testing in asymptomatic chronic nonischemic mitral regurgitation. Am J Cardiol. 2007 ; 100 : 1274-81.
PubMed
48) Ha JW, Choi D, Park S, Shim CY, Kim JM, Moon SH, Lee HJ, Choi EY and Chung N. Determinants of exercise-induced pulmonary hypertension in patients with normal left ventricular ejection fraction. Heart. 2009 ; 95 : 490-4.
PubMed
49) Tischler MD, Battle RW, Saha M, Niggel J and LeWinter MM. Observations suggesting a high incidence of exercise-induced severe mitral regurgitation in patients with mild rheumatic mitral valve disease at rest. J Am Coll Cardiol. 1995 ; 25 : 128-33.
 
50) Lee R, Haluska B, Leung DY, Case C, Mundy J and Marwick TH. Functional and prognostic implications of left ventricular contractile reserve in patients with asymptomatic severe mitral regurgitation. Heart. 2005 ; 91 : 1407-12.
PubMed
51) Lancellotti P, Cosyns B, Zacharakis D, Attena E, Van Camp G, Gach O, Radermecker M and Pierard LA. Importance of left ventricular longitudinal function and functional reserve in patients with degenerative mitral regurgitation : assessment by two-dimensional speckle tracking. J Am Soc Echocardiogr. 2008 ; 21 : 1331-6.
PubMed
52) Rizzello V, Poldermans D, Boersma E, Biagini E, Schinkel AF, Krenning B, Elhendy A, Vourvouri EC, Sozzi FB, Maat A, Crea F, Roelandt JR and Bax JJ. Opposite patterns of left ventricular remodeling after coronary revascularization in patients with ischemic cardiomyopathy : role of myocardial viability. Circulation. 2004 ; 110 : 2383-8.
PubMed
53) Lancellotti P, Troisfontaines P, Toussaint AC and Pierard LA. Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction. Circulation. 2003 ; 108 : 1713-7.
PubMed
54) Pierard LA and Lancellotti P. The role of ischemic mitral regurgitation in the pathogenesis of acute pulmonary edema. N Engl J Med. 2004 ; 351 : 1627-34.
PubMed
55) Chung H, Amaki M, Takashio S, Takahama H, Ohara T, Hasegawa T, Sugano Y, Fujita T, Kobayashi J, Asakura M, Kanzaki H, Anzai T and Kitakaze M. Effect of Mitral Valve Surgery in Patients With Dilated Cardiomyopathy and Severe Functional Mitral Regurgitation. Circulation journal : official journal of the Japanese Circulation Society. 2017 ; 82 : 131-40.
PubMed
56) Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ and Mack MJ. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. The New England journal of medicine. 2018 ; 379 : 2307-18.
 
57) Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel R, Rose GA, Engeron E, Loghin C, Trento A, Skipper ER, Fudge T, Letsou GV, Massaro JM and Mauri L. Percutaneous repair or surgery for mitral regurgitation. The New England journal of medicine. 2011 ; 364 : 1395-406.
PubMed
58) Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, Ogai A, Asakura M, Kim J, Minamino T, Takashima S, Sanada S, Sugimachi M, Komamura K, Mochizuki N and Kitakaze M. Metformin prevents progression of heart failure in dogs : role of AMP-activated protein kinase. Circulation. 2009 ; 119 : 2568-77.
PubMed
59) Yoshida A, Ishibashi-Ueda H, Yamada N, Kanzaki H, Hasegawa T, Takahama H, Amaki M, Asakura M and Kitakaze M. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. European journal of heart failure. 2013 ; 15 : 166-75.
PubMed
60) Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I and Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. Journal of the American College of Cardiology. 1992 ; 19 : 1550-8.
 
61) Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Santucci A, Santucci C, Reboldi G and Porcellati C. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. The American journal of cardiology. 1996 ; 78 : 197-202.
PubMed
62) Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G and Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998 ; 97 : 48-54.
PubMed
63) Schillaci G, Pasqualini L, Verdecchia P, Vaudo G, Marchesi S, Porcellati C, de Simone G and Mannarino E. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. Journal of the American College of Cardiology. 2002 ; 39 : 2005-11.
PubMed
64) Wachtell K, Palmieri V, Gerdts E, Bella JN, Aurigemma GP, Papademetriou V, Dahlof B, Aalto T, Ibsen H, Rokkedal JE and Devereux RB. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). The American journal of cardiology. 2010 ; 106 : 999-1005.
 
65) Redfield MM, Jacobsen SJ, Burnett JC, Jr., Mahoney DW, Bailey KR and Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community : appreciating the scope of the heart failure epidemic. Jama. 2003 ; 289 : 194-202.
PubMed
66) Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL and Redfield MM. Diastolic dysfunction and left atrial volume : a population-based study. Journal of the American College of Cardiology. 2005 ; 45 : 87-92.
PubMed
67) Dahlof B, Pennert K and Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. American journal of hypertension. 1992 ; 5 : 95-110.
PubMed
68) Levy D, Garrison RJ, Savage DD, Kannel WB and Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. The New England journal of medicine. 1990 ; 322 : 1561-6.
PubMed
69) Wright JT, Jr., Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK and Habib GB. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. Jama. 2005 ; 293 : 1595-608.
PubMed
70) Ishii K, Imai M, Suyama T, Maenaka M, Nagai T, Kawanami M and Seino Y. Exercise-induced post-ischemic left ventricular delayed relaxation or diastolic stunning : is it a reliable marker in detecting coronary artery disease? Journal of the American College of Cardiology. 2009 ; 53 : 698-705.
PubMed
71) Hozumi T, Yoshida K, Ogata Y, Akasaka T, Asami Y, Takagi T and Morioka S. Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation. 1998 ; 97 : 1557-62.
PubMed
72) Manson AL, Nudelman SP, Hagley MT, Hall AF and Kovacs SJ. Relationship of the third heart sound to transmitral flow velocity deceleration. Circulation. 1995 ; 92 : 388-94.
PubMed
73) Drazner MH, Rame JE, Stevenson LW and Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. The New England journal of medicine. 2001 ; 345 : 574-81.
 
74) Stevenson LW and Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. Jama. 1989 ; 261 : 884-8.
PubMed
75) Edwards P and Cohen GI. Both diastolic and systolic function alternate in pulsus alternans : a case report and review. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2003 ; 16 : 695-7.
 
76) Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH and Stevenson LW. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. Journal of the American College of Cardiology. 2003 ; 41 : 1797-804.
PubMed
77) Cotter G, Moshkovitz Y, Kaluski E, Milo O, Nobikov Y, Schneeweiss A, Krakover R and Vered Z. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. European journal of heart failure. 2003 ; 5 : 443-51.
PubMed
78) Forrester JS, Diamond GA and Swan HJ. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. The American journal of cardiology. 1977 ; 39 : 137-45.
PubMed
79) Patterson SW and Starling EH. On the mechanical factors which determine the output of the ventricles. The Journal of physiology. 1914 ; 48 : 357-79.
PubMed
80) Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB and Fonarow GC. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. Jama. 2006 ; 296 : 2217-26.
PubMed
81) Jain P, Massie BM, Gattis WA, Klein L and Gheorghiade M. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. American heart journal. 2003 ; 145 : S3-17.
PubMed
82) 岩橋正, 山辺裕, 船越 貴, 花岡淳, 安部博 and 横山光. 第41回循環器負荷研究会 慢性心不全の臨床評価における6分間歩行検査の意義. 心臓. 1997 ; 29 : 62-5.
 
83) Sliwa K, Norton GR, Kone N, Candy G, Kachope J, Woodiwiss AJ, Libhaber C, Sareli P and Essop R. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. Journal of the American College of Cardiology. 2004 ; 44 : 1825-30.
 
84) Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P and Lechat P. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence : results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005 ; 112 : 2426-35.
PubMed
85) Ahmed A, Rich MW, Sanders PW, Perry GJ, Bakris GL, Zile MR, Love TE, Aban IB and Shlipak MG. Chronic kidney disease associated mortality in diastolic versus systolic heart failure : a propensity matched study. The American journal of cardiology. 2007 ; 99 : 393-8.
 
86) Imazu M, Takahama H, Shindo K, Hasegawa T, Kanzaki H, Anzai T, Asanuma H, Morita T, Asakura M and Kitakaze M. A Pathophysiological Role of Plasma Indoxyl Sulfate in Patients with Heart Failure. International Journal of Gerontology. 2017 ; 11 : 62-6.
 
87) Asanuma H, Chung H, Ito S, Min KD, Ihara M, Takahama H, Funayama M, Imazu M, Fukuda H, Ogai A, Asano Y, Minamino T, Takashima S, Morita T, Sugimachi M, Asakura M and Kitakaze M. AST-120, an Adsorbent of Uremic Toxins, Improves the Pathophysiology of Heart Failure in Conscious Dogs. Cardiovascular drugs and therapy. 2019 ; 33 : 277-86.
PubMed
88) Tonelli M, Sacks F, Pfeffer M, Gao Z and Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005 ; 112 : 2627-33.
PubMed
89) Yamashita T, Yoshioka M and Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000 ; 277 : 494-8.
PubMed
90) Consortium A. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000 ; 26 : 345-8.
 
91) Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S and Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001 ; 98 : 6500-5.
PubMed
92) Coe LM, Madathil SV, Casu C, Lanske B, Rivella S and Sitara D. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem. 2014 ; 289 : 9795-810.
PubMed
93) Wolf M, Koch TA and Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013 ; 28 : 1793-803.
PubMed
94) Liu S, Tang W, Zhou J, Vierthaler L and Quarles LD. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. American journal of physiology Endocrinology and metabolism. 2007 ; 293 : E1636-44.
PubMed
95) Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R and Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997 ; 390 : 45-51.
PubMed
96) Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S and Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006 ; 444 : 770-4.
 
97) Nabeshima Y. Discovery of alpha-Klotho unveiled new insights into calcium and phosphate homeostasis. Proc Jpn Acad Ser B Phys Biol Sci. 2009 ; 85 : 125-41.
PubMed
98) Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H and Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008 ; 359 : 584-92.
 
99) Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M and Chronic Renal Insufficiency Cohort Study G. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011 ; 305 : 2432-9.
 
100) Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie HL, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CAM, Lash JP, Hsu CY, Leonard MB, Wolf M and Grp CS. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011 ; 79 : 1370-8.
 
101) Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010 ; 21 : 1427-35.
PubMed
102) Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M and Investigators H. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol. 2011 ; 22 : 1913-22.
 
103) Plischke M, Neuhold S, Adlbrecht C, Bielesz B, Shayganfar S, Bieglmayer C, Szekeres T, Horl WH, Strunk G, Vavken P, Pacher R and Hulsmann M. Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Invest. 2012 ; 42 : 649-56.
PubMed
104) Wohlfahrt P, Melenovsky V, Kotrc M, Benes J, Jabor A, Franekova J, Lemaire S, Kautzner J and Jarolim P. Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure. JACC Heart Fail. 2015 ; 3 : 829-39.
PubMed
105) Imazu M, Takahama H, Asanuma H, Funada A, Sugano Y, Ohara T, Hasegawa T, Asakura M, Kanzaki H, Anzai T and Kitakaze M. Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease. American journal of physiology Heart and circulatory physiology. 2014 ; 307 : H1504-11.
PubMed
106) Takeshita K, Fujimori T, Kurotaki Y, Honjo H, Tsujikawa H, Yasui K, Lee JK, Kamiya K, Kitaichi K, Yamamoto K, Ito M, Kondo T, Iino S, Inden Y, Hirai M, Murohara T, Kodama I and Nabeshima Y. Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation. 2004 ; 109 : 1776-82.
PubMed
107) Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG and Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011 ; 121 : 4393-408.
 
108) Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstadt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M and Faul C. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab. 2015 ; 22 : 1020-32.
PubMed
109) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes care. 2003 ; 26 Suppl 1 : S5-20.
 
110) Rajala U, Laakso M, Qiao Q and Keinanen-Kiukaanniemi S. Prevalence of retinopathy in people with diabetes, impaired glucose tolerance, and normal glucose tolerance. Diabetes care. 1998 ; 21 : 1664-9.
PubMed
111) Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Carstensen B, Tajima N, Iwamoto Y, Borch-Johnsen K and Borch-Jonsen K. The fasting plasma glucose cut-point predicting a diabetic 2-h OGTT glucose level depends on the phenotype. Diabetes research and clinical practice. 2002 ; 55 : 35-43.
PubMed
112) Kim J, Nakatani S, Hashimura K, Komamura K, Kanzaki H, Asakura M, Asanuma H, Kokubo Y, Tomoike H and Kitakaze M. Abnormal glucose tolerance contributes to the progression of chronic heart failure in patients with dilated cardiomyopathy. Hypertension research : official journal of the Japanese Society of Hypertension. 2006 ; 29 : 775-82.
 
113) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Jama. 2002 ; 288 : 2981-97.
 
114) Niewoehner DE. Clinical practice. Outpatient management of severe COPD. The New England journal of medicine. 2010 ; 362 : 1407-16.
PubMed
115) Le Jemtel TH, Padeletti M and Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. Journal of the American College of Cardiology. 2007 ; 49 : 171-80.
PubMed
116) Khawaja FJ, Shah ND, Lennon RJ, Slusser JP, Alkatib AA, Rihal CS, Gersh BJ, Montori VM, Holmes DR, Bell MR, Curtis JP, Krumholz HM and Ting HH. Factors associated with 30-day readmission rates after percutaneous coronary intervention. Archives of internal medicine. 2012 ; 172 : 112-7.
PubMed
117) Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E, Jr. and She D. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Annals of epidemiology. 2006 ; 16 : 63-70.
PubMed
118) Sin DD, Wu L and Man SF. The relationship between reduced lung function and cardiovascular mortality : a population-based study and a systematic review of the literature. Chest. 2005 ; 127 : 1952-9.
 
119) Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, Jiang R, Kawut SM, Kronmal RA, Lima JA, Shahar E, Smith LJ and Watson KE. Percent emphysema, airflow obstruction, and impaired left ventricular filling. The New England journal of medicine. 2010 ; 362 : 217-27.
PubMed
120) Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, Yokota T, Takeshita A, Yokoshiki H and Tsutsui H. Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized with heart failure in Japan. A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circulation journal : official journal of the Japanese Circulation Society. 2009 ; 73 : 1901-8.
PubMed
121) Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA and Ponikowski P. Ferric carboxymaltose in patients with heart failure and iron deficiency. The New England journal of medicine. 2009 ; 361 : 2436-48.
PubMed
122) Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU and Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. The New England journal of medicine. 2006 ; 355 : 2071-84.
PubMed
123) Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M and Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. The New England journal of medicine. 2006 ; 355 : 2085-98.
PubMed
124) Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD and Toto R. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. The New England journal of medicine. 2009 ; 361 : 2019-32.
PubMed
125) Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M and van Veldhuisen DJ. Treatment of anemia with darbepoetin alfa in systolic heart failure. The New England journal of medicine. 2013 ; 368 : 1210-9.
PubMed
126) Lenneman CG and Sawyer DB. Cardio-Oncology : An Update on Cardiotoxicity of Cancer-Related Treatment. Circulation research. 2016 ; 118 : 1008-20.
PubMed
127) Tu H, Wen CP, Tsai SP, Chow WH, Wen C, Ye Y, Zhao H, Tsai MK, Huang M, Dinney CP, Tsao CK and Wu X. Cancer risk associated with chronic diseases and disease markers : prospective cohort study. BMJ (Clinical research ed). 2018 ; 360 : k134.
 
128) Sakamoto M, Hasegawa T, Asakura M, Kanzaki H, Takahama H, Amaki M, Mochizuki N, Anzai T, Hamasaki T and Kitakaze M. Does the pathophysiology of heart failure prime the incidence of cancer? Hypertension research : official journal of the Japanese Society of Hypertension. 2017 ; 40 : 831-6.
PubMed
129) Hasin T, Gerber Y, McNallan SM, Weston SA, Kushwaha SS, Nelson TJ, Cerhan JR and Roger VL. Patients with heart failure have an increased risk of incident cancer. Journal of the American College of Cardiology. 2013 ; 62 : 881-6.
 
130) Narumi T, Watanabe T, Kadowaki S, Takahashi T, Yokoyama M, Kinoshita D, Honda Y, Funayama A, Nishiyama S, Takahashi H, Arimoto T, Shishido T, Miyamoto T and Kubota I. Sarcopenia evaluated by fat-free mass index is an important prognostic factor in patients with chronic heart failure. European journal of internal medicine. 2015 ; 26 : 118-22.
PubMed
131) Dos Santos MR, Saitoh M, Ebner N, Valentova M, Konishi M, Ishida J, Emami A, Springer J, Sandek A, Doehner W, Anker SD and von Haehling S. Sarcopenia and Endothelial Function in Patients With Chronic Heart Failure : Results From the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). Journal of the American Medical Directors Association. 2017 ; 18 : 240-5.
PubMed
132) Vidan MT, Blaya-Novakova V, Sanchez E, Ortiz J, Serra-Rexach JA and Bueno H. Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. European journal of heart failure. 2016 ; 18 : 869-75.
 
133) Denfeld QE, Winters-Stone K, Mudd JO, Hiatt SO, Chien CV and Lee CS. Frequency of and Significance of Physical Frailty in Patients With Heart Failure. The American journal of cardiology. 2017 ; 119 : 1243-9.
 
134) Abdul-Rahim AH, Perez AC, Fulton RL, Jhund PS, Latini R, Tognoni G, Wikstrand J, Kjekshus J, Lip GY, Maggioni AP, Tavazzi L, Lees KR and McMurray JJ. Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation : Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell' Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials. Circulation. 2015 ; 131 : 1486-94 ; discussion 1494.
PubMed
135) Ouchi N, Ohashi K, Shibata R and Murohara T. Protective roles of adipocytokines and myokines in cardiovascular disease. Circulation Journal. 2016 : CJ-16-0663.
 
136) Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T and Hori M. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction : comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circulation journal : official journal of the Japanese Circulation Society. 2013 ; 77 : 908-16.
 
137) Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG and Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (London, England). 1993 ; 342 : 1441-6.
 
138) Effect of metoprolol CR/XL in chronic heart failure : Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (London, England). 1999 ; 353 : 2001-7.
 
139) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial. Lancet (London, England). 1999 ; 353 : 9-13.
 
140) Henry Krum, Ellen B Roecker, Paul Mohacsi, Jean L Rouleau, Michal Tendera, Andrew J S Coats, Hugo A Katus, Michael B Fowler, Milton Packer, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure : results from the COPERNICUS Study,JAMA 2003 Feb 12 ; 289 (6) : 712-8.
 
141) Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure : meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet (London, England). 1997 ; 350 : 1417-24.
 
142) Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G and Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT) : a randomised placebo-controlled study. Lancet (London, England). 2010 ; 376 : 875-85.
 
143) Tsutsui H, Momomura S-i, Yamashina A, Shimokawa H, Kihara Y, Saito Y, Hagiwara N, Ito H, Yano M and Yamamoto K. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure-J-SHIFT study-. Circulation Journal. 2019 : CJ-19-0227.
 
144) McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K and Zile MR. Angiotensin-neprilysin inhibition versus enalapril in heart failure. The New England journal of medicine. 2014 ; 371 : 993-1004.
PubMed
145) Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Ohishi T, Okino N, Kitamura T and Guo W. Angiotensin Receptor Neprilysin Inhibitor in Japanese Patients With Heart Failure and Reduced Ejection Fraction - Baseline Characteristics and Treatment of PARALLEL-HF Trial. Circulation journal : official journal of the Japanese Circulation Society. 2018 ; 82 : 2575-83.
 
146) Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J and O'Connor CM. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. The New England journal of medicine. 2020 ; 382 : 1883-93.
 
147) McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M and Langkilde AM. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England journal of medicine. 2019 ; 381 : 1995-2008.
PubMed
148) Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, DeMets DL, Inzucchi SE, Kober L, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Lindholm D, Niklasson A, Sjostrand M, Langkilde AM and McMurray JJV. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction : Results From the DAPA-HF Trial. Circulation. 2020 ; 141 : 90-9.
PubMed
149) Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F and Packer M. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction : rationale for and design of the EMPEROR-Preserved Trial. European journal of heart failure. 2019 ; 21 : 1279-87.
 
150) Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Anker SD and Zannad F. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction : rationale for and design of the EMPEROR-Reduced trial. European journal of heart failure. 2019 ; 21 : 1270-8.
 
151) Baartscheer A, Schumacher CA, Wust RC, Fiolet JW, Stienen GJ, Coronel R and Zuurbier CJ. Empagliflozin decreases myocardial cytoplasmic Na (+) through inhibition of the cardiac Na (+)/H (+) exchanger in rats and rabbits. Diabetologia. 2017 ; 60 : 568-73.
PubMed
152) Liu T, Takimoto E, Dimaano VL, DeMazumder D, Kettlewell S, Smith G, Sidor A, Abraham TP and O'Rourke B. Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure. Circulation research. 2014 ; 115 : 44-54.
 
153) Kraakman MJ, Lee MK, Al-Sharea A, Dragoljevic D, Barrett TJ, Montenont E, Basu D, Heywood S, Kammoun HL, Flynn M, Whillas A, Hanssen NM, Febbraio MA, Westein E, Fisher EA, Chin-Dusting J, Cooper ME, Berger JS, Goldberg IJ, Nagareddy PR and Murphy AJ. Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes. The Journal of clinical investigation. 2017 ; 127 : 2133-47.
 
154) Ferrannini E, Mark M and Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial : A "Thrifty Substrate" Hypothesis. Diabetes care. 2016 ; 39 : 1108-14.
 
155) Sano M. A new class of drugs for heart failure : SGLT2 inhibitors reduce sympathetic overactivity. Journal of cardiology. 2018 ; 71 : 471-6.
 
156) Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF, Jr., Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsanyi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI and Honarpour N. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF) : a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet (London, England). 2016 ; 388 : 2895-903.
 
157) Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, Henze M, Kawas R, Oslob JD, Rodriguez HM, Song Y, Wan W, Leinwand LA, Spudich JA, McDowell RS, Seidman JG and Seidman CE. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science (New York, NY). 2016 ; 351 : 617-21.
 
158) Rohde JA, Roopnarine O, Thomas DD and Muretta JM. Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin. Proceedings of the National Academy of Sciences of the United States of America. 2018 ; 115 : E7486-e7494.
PubMed
159) Stern JA, Markova S, Ueda Y, Kim JB, Pascoe PJ, Evanchik MJ, Green EM and Harris SP. A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy. PloS one. 2016 ; 11 : e0168407.
PubMed
160) Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D, Lambing J, Lee J, Semigran M and Sehnert AJ. Mavacamten treatment for obstructive hypertrophic cardiomyopathy : a clinical trial. Annals of internal medicine. 2019 ; 170 : 741-8.
PubMed
161) Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP and Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) : a randomised double-blind trial. Lancet (London, England). 2002 ; 360 : 196-202.
 
162) Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS and Lie KI. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). European heart journal. 2002 ; 23 : 1422-32.
 
163) Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P and Kivikko M. Levosimendan vs dobutamine for patients with acute decompensated heart failure : the SURVIVE Randomized Trial. Jama. 2007 ; 297 : 1883-91.
PubMed
164) Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL and Cotter G. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF) : a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet (London, England). 2009 ; 373 : 1429-39.
 
165) Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F and Fleming T. Targeted anticytokine therapy in patients with chronic heart failure : results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004 ; 109 : 1594-602.
PubMed
166) Cleland JG, Swedberg K and Poole-Wilson PA. Successes and failures of current treatment of heart failure. Lancet (London, England). 1998 ; 352 Suppl 1 : Si19-28.
 
167) Cheng TO. Hippocrates and cardiology. American heart journal. 2001 ; 141 : 173-83.
PubMed
168) Withering W. An account of the foxglove, and some of its medical uses : Cambridge University Press ; 2014.
 
169) 堀正二 and 朝野仁裕. 3. 心不全. 日本内科学会雑誌. 2002 ; 91 : 880-6.
 
170) Guyton AC. Circulatory physiology. Cardiac output and its regulation. 1973.
PubMed
171) Suga H, Sagawa K and Shoukas AA. Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circulation research. 1973 ; 32 : 314-22.
PubMed
172) Group XiSHFS. Xamoterol in severe heart failure. The Lancet. 1990 ; 336 : 1-6.
 
173) A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group. Cardiovascular drugs and therapy. 1990 ; 4 : 419-25.
 
174) Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F, 3rd, DeMets DL and White BG. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. The New England journal of medicine. 1998 ; 339 : 1810-6.
 
175) Kitakaze M, Weisman HF and Marban E. Contractile dysfunction and ATP depletion after transient calcium overload in perfused ferret hearts. Circulation. 1988 ; 77 : 685-95.
PubMed
176) Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Remme WJ, Heinrich-Nols J, Dumont JM and Seed P. Effect of pimobendan on exercise capacity in patients with heart failure : main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart (British Cardiac Society). 1996 ; 76 : 223-31.
PubMed
177) Fukuda H, Shindo K, Sakamoto M, Ide T, Kinugawa S, Fukushima A, Tsutsui H, Ito S, Ishii A, Washio T and Kitakaze M. Elucidation of the Strongest Predictors of Cardiovascular Events in Patients with Heart Failure. EBioMedicine. 2018 ; 33 : 185-95.
PubMed
178) Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA and Jolly MK. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. The New England journal of medicine. 1993 ; 329 : 1-7.
 
179) The effect of digoxin on mortality and morbidity in patients with heart failure. The New England journal of medicine. 1997 ; 336 : 525-33.
PubMed
180) Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L and investigators S. Ivabradine and outcomes in chronic heart failure (SHIFT) : a randomised placebo-controlled study. The Lancet. 2010 ; 376 : 875-85.
 
181) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The New England journal of medicine. 1987 ; 316 : 1429-35.
PubMed
182) Packer M. Presentation of the results of the Prospective Randomized Amlodipine Survival Evaluation-2 Trial (PRAISE-2) at the American College of Cardiology Scientific Sessions. Anaheim, CA, March. 2000 ; 15 : 2000.
 
183) Cabell CH, Trichon BH, Velazquez EJ, Dumesnil JG, Anstrom KJ, Ryan T, Miller AB, Belkin RN, Cropp AB and O'Connor CM. Importance of echocardiography in patients with severe nonischemic heart failure : the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study. American heart journal. 2004 ; 147 : 151-7.
 
184) Kangawa K and Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochemical and biophysical research communications. 1984 ; 118 : 131-9.
PubMed
185) O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM and McMurray JJ. Effect of nesiritide in patients with acute decompensated heart failure. The New England journal of medicine. 2011 ; 365 : 32-43.
PubMed
186) Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T and Ohara T. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND) : two randomised trials. The Lancet. 2007 ; 370 : 1483-93.
 
187) Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P, Keren A, Motro M, Moye LA, Otterstad JE, Pratt CM, Ponikowski P, Rouleau JL, Sestier F, Winkelmann BR and Young JB. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial) : a placebo-controlled randomised trial. Lancet (London, England). 2008 ; 371 : 228-36.
 
188) Yoshikawa T, Baba A, Akaishi M, Wakabayashi Y, Monkawa T, Kitakaze M, Izumi T and Tomoike H. Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column-A prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety. Journal of clinical apheresis. 2016 ; 31 : 535-44.
PubMed
189) Funaya H, Kitakaze M, Node K, Minamino T, Komamura K and Hori M. Plasma adenosine levels increase in patients with chronic heart failure. Circulation. 1997 ; 95 : 1363-5.
PubMed
190) Winlaw DS, Smythe GA, Keogh AM, Schyvens CG, Spratt PM and Macdonald PS. Increased nitric oxide production in heart failure. Lancet (London, England). 1994 ; 344 : 373-4.
 
191) Franciosa JA, Nordstrom LA and Cohn JN. Nitrate therapy for congestive heart failure. Jama. 1978 ; 240 : 443-6.
PubMed
192) Hori M and Kitakaze M. Adenosine, the heart, and coronary circulation. Hypertension (Dallas, Tex : 1979). 1991 ; 18 : 565-74.
 
193) Kitakaze M, Minamino T, Node K, Takashima S, Funaya H, Kuzuya T and Hori M. Adenosine and cardioprotection in the diseased heart. Japanese circulation journal. 1999 ; 63 : 231-43.
PubMed
194) Kitakaze M, Minamino T, Node K, Koretsune Y, Komamura K, Funaya H, Kuzuya T and Hori M. Elevation of plasma adenosine levels may attenuate the severity of chronic heart failure. Cardiovascular drugs and therapy. 1998 ; 12 : 307-9.
PubMed
195) Sanada S, Asanuma H, Koretsune Y, Watanabe K, Nanto S, Awata N, Hoki N, Fukunami M, Kitakaze M and Hori M. Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure : a prospective open-randomized study. Hypertension research : official journal of the Japanese Society of Hypertension. 2007 ; 30 : 913-9.
PubMed
196) Cyranoski D. 'Reprogrammed' stem cells approved to mend human hearts for the first time. Nature. 2018 ; 557 : 619-20.
PubMed
197) Kawamura T, Miyagawa S, Fukushima S, Maeda A, Kashiyama N, Kawamura A, Miki K, Okita K, Yoshida Y and Shiina T. Cardiomyocytes derived from MHC-homozygous induced pluripotent stem cells exhibit reduced allogeneic immunogenicity in MHC-matched non-human primates. Stem cell reports. 2016 ; 6 : 312-20.
PubMed
198) Yoshida Y and Yamanaka S. Induced pluripotent stem cells 10 years later : for cardiac applications. Circulation research. 2017 ; 120 : 1958-1968.
PubMed
199) Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, Barnard D, Bouchard A, Jaski B, Lyon AR, Pogoda JM, Rudy JJ and Zsebo KM. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2) : a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet (London, England). 2016 ; 387 : 1178-86.
 
200) Hodatsu A, Fujino N, Uyama Y, Tsukamoto O, Imai-Okazaki A, Yamazaki S, Seguchi O, Konno T, Hayashi K, Kawashiri MA, Asano Y, Kitakaze M, Takashima S and Yamagishi M. Impact of cardiac myosin light chain kinase gene mutation on development of dilated cardiomyopathy. ESC heart failure. 2019 ; 6 : 406-15.
PubMed
201) Tobita T, Nomura S, Morita H, Ko T, Fujita T, Toko H, Uto K, Hagiwara N, Aburatani H and Komuro I. Identification of MYLK3 mutations in familial dilated cardiomyopathy. Scientific reports. 2017 ; 7 : 17495.
PubMed
202) Tsukamoto O and Kitakaze M. Biochemical and physiological regulation of cardiac myocyte contraction by cardiac-specific myosin light chain kinase. Circulation journal : official journal of the Japanese Circulation Society. 2013 ; 77 : 2218-25.
PubMed
203) Braunwald E and Selwyn A. The myocardium ; failure and infarction : HP Pub. Co. ; 1974.
 
204) Kentish JC, ter Keurs HE, Ricciardi L, Bucx JJ and Noble MI. Comparison between the sarcomere length-force relations of intact and skinned trabeculae from rat right ventricle. Influence of calcium concentrations on these relations. Circulation research. 1986 ; 58 : 755-68.
PubMed
205) Okada K, Minamino T, Tsukamoto Y, Liao Y, Tsukamoto O, Takashima S, Hirata A, Fujita M, Nagamachi Y, Nakatani T, Yutani C, Ozawa K, Ogawa S, Tomoike H, Hori M and Kitakaze M. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction : possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation. 2004 ; 110 : 705-12.
PubMed
206) Okada K, Minamino T and Kitakaze M. [ Role of endoplasmic reticulum stress in hypertrophic and failing hearts]. Nihon yakurigaku zasshi Folia pharmacologica Japonica. 2005 ; 126 : 385-9.
PubMed
207) Daniels M, Noble MI, ter Keurs HE and Wohlfart B. Velocity of sarcomere shortening in rat cardiac muscle : relationship to force, sarcomere length, calcium and time. The Journal of physiology. 1984 ; 355 : 367-81.
PubMed
208) Sonnenblick EH. Force-velocity relations in mammalian heart muscle. The American journal of physiology. 1962 ; 202 : 931-9.
PubMed
209) Suga H, Sagawa K and Kostiuk DP. Controls of ventricular contractility assessed by pressure-volume ration, Emax. Cardiovascular research. 1976 ; 10 : 582-92.
PubMed
210) Kitakaze M and Marban E. Cellular mechanism of the modulation of contractile function by coronary perfusion pressure in ferret hearts. The Journal of physiology. 1989 ; 414 : 455-72.
PubMed
211) Fabiato A and Fabiato F. Dependence of the contractile activation of skinned cardiac cells on the sarcomere length. Nature. 1975 ; 256 : 54-6.
PubMed
212) McLaurin LP, Rolett EL and Grossman W. Impaired left ventricular relaxation during pacing-induced ischemia. The American journal of cardiology. 1973 ; 32 : 751-7.
PubMed
213) Taw R, Griffith L, Conti C, Ducci H and Weisfeldt M. Impaired isovolumic relaxation during pacing induced ischemia in man. Circulation. 1976 ; 54 : 6-6.
 
214) Mann T, Goldberg S, Mudge GH, Jr. and Grossman W. Factors contributing to altered left ventricular diastolic properties during angina pectoris. Circulation. 1979 ; 59 : 14-20.
PubMed
215) Yue DT. Intracellular [Ca2+] related to rate of force development in twitch contraction of heart. The American journal of physiology. 1987 ; 252 : H760-70.
PubMed
216) Kaufmann RL, Bayer RM and Harnasch C. Autoregulation of contractility in the myocardial cell. Displacement as a controlling parameter. Pflugers Archiv : European journal of physiology. 1972 ; 332 : 96-116.
PubMed
217) Lompre AM, Nadal-Ginard B and Mahdavi V. Expression of the cardiac ventricular alpha- and beta-myosin heavy chain genes is developmentally and hormonally regulated. The Journal of biological chemistry. 1984 ; 259 : 6437-46.
 
218) Izumo S, Lompre AM, Matsuoka R, Koren G, Schwartz K, Nadal-Ginard B and Mahdavi V. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. The Journal of clinical investigation. 1987 ; 79 : 970-7.
PubMed
219) Anderson PA, Malouf NN, Oakeley AE, Pagani ED and Allen PD. Troponin T isoform expression in humans. A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circulation research. 1991 ; 69 : 1226-33.
PubMed
220) Seguchi O, Takashima S, Yamazaki S, Asakura M, Asano Y, Shintani Y, Wakeno M, Minamino T, Kondo H, Furukawa H, Nakamaru K, Naito A, Takahashi T, Ohtsuka T, Kawakami K, Isomura T, Kitamura S, Tomoike H, Mochizuki N and Kitakaze M. A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. The Journal of clinical investigation. 2007 ; 117 : 2812-24.
PubMed
221) Chan JY, Takeda M, Briggs LE, Graham mL, Lu JT, Horikoshi N, Weinberg EO, Aoki H, Sato N, Chien KR and Kasahara H. Identification of cardiac-specific myosin light chain kinase. Circulation research. 2008 ; 102 : 571-80.
PubMed
222) Hwang PM and Sykes BD. Targeting the sarcomere to correct muscle function. Nature reviews Drug discovery. 2015 ; 14 : 313-28.
PubMed
223) Scruggs SB, Hinken AC, Thawornkaiwong A, Robbins J, Walker LA, de Tombe PP, Geenen DL, Buttrick PM and Solaro RJ. Ablation of ventricular myosin regulatory light chain phosphorylation in mice causes cardiac dysfunction in situ and affects neighboring myofilament protein phosphorylation. The Journal of biological chemistry. 2009 ; 284 : 5097-106.
PubMed
224) Sanbe A, Fewell JG, Gulick J, Osinska H, Lorenz J, Hall DG, Murray LA, Kimball TR, Witt SA and Robbins J. Abnormal cardiac structure and function in mice expressing nonphosphorylatable cardiac regulatory myosin light chain 2. The Journal of biological chemistry. 1999 ; 274 : 21085-94.
PubMed
225) Ding P, Huang J, Battiprolu PK, Hill JA, Kamm KE and Stull JT. Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardiac performance in vivo. The Journal of biological chemistry. 2010 ; 285 : 40819-29.
PubMed
226) Sheikh F, Ouyang K, Campbell SG, Lyon RC, Chuang J, Fitzsimons D, Tangney J, Hidalgo CG, Chung CS, Cheng H, Dalton ND, Gu Y, Kasahara H, Ghassemian M, Omens JH, Peterson KL, Granzier HL, Moss RL, McCulloch AD and Chen J. Mouse and computational models link Mlc2v dephosphorylation to altered myosin kinetics in early cardiac disease. The Journal of clinical investigation. 2012 ; 122 : 1209-21.
 
227) Tsukamoto O. Direct Sarcomere Modulators Are Promising New Treatments for Cardiomyopathies. International journal of molecular sciences. 2019 ; 21.
PubMed
228) Ferrari MB, Ribbeck K, Hagler DJ and Spitzer NC. A calcium signaling cascade essential for myosin thick filament assembly in Xenopus myocytes. The Journal of cell biology. 1998 ; 141 : 1349-56.
PubMed
229) Du A, Sanger JM, Linask KK and Sanger JW. Myofibrillogenesis in the first cardiomyocytes formed from isolated quail precardiac mesoderm. Developmental biology. 2003 ; 257 : 382-94.
PubMed
230) Aoki H, Sadoshima J and Izumo S. Myosin light chain kinase mediates sarcomere organization during cardiac hypertrophy in vitro. Nature medicine. 2000 ; 6 : 183-8.
PubMed
231) Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W and Morgan JP. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circulation research. 1987 ; 61 : 70-6.
PubMed
232) Hayashi T, Asano Y, Shintani Y, Aoyama H, Kioka H, Tsukamoto O, Hikita M, Shinzawa-Itoh K, Takafuji K, Higo S, Kato H, Yamazaki S, Matsuoka K, Nakano A, Asanuma H, Asakura M, Minamino T, Goto Y, Ogura T, Kitakaze M, Komuro I, Sakata Y, Tsukihara T, Yoshikawa S and Takashima S. Higd1a is a positive regulator of cytochrome c oxidase. Proceedings of the National Academy of Sciences of the United States of America. 2015 ; 112 : 1553-8.
PubMed
233) Kioka H, Kato H, Fujikawa M, Tsukamoto O, Suzuki T, Imamura H, Nakano A, Higo S, Yamazaki S, Matsuzaki T, Takafuji K, Asanuma H, Asakura M, Minamino T, Shintani Y, Yoshida M, Noji H, Kitakaze M, Komuro I, Asano Y and Takashima S. Evaluation of intramitochondrial ATP levels identifies G0/G1 switch gene 2 as a positive regulator of oxidative phosphorylation. Proceedings of the National Academy of Sciences of the United States of America. 2014 ; 111 : 273-8.
PubMed
234) Kioka H, Kato H, Fujita T, Asano Y, Shintani Y, Yamazaki S, Tsukamoto O, Imamura H, Kogo M, Kitakaze M, Sakata Y and Takashima S. In vivo real-time ATP imaging in zebrafish hearts reveals G0s2 induces ischemic tolerance. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2020 ; 34 : 2041-54.
PubMed
235) Li M, Zheng C, Sato T, Kawada T, Sugimachi M and Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation. 2004 ; 109 : 120-4.
PubMed
236) Li M, Zheng C, Kawada T, Inagaki M, Uemura K, Shishido T and Sugimachi M. Donepezil markedly improves long-term survival in rats with chronic heart failure after extensive myocardial infarction. Circulation journal : official journal of the Japanese Circulation Society. 2013 ; 77 : 2519-25.
PubMed
237) Zile MR and Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure : Part I : diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002 ; 105 : 1387-93.
PubMed
238) Elzinga G and Westerhof N. Pressure and flow generated by the left ventricle against different impedances. Circulation research. 1973 ; 32 : 178-86.
PubMed
239) Hori M, Inoue M, Kitakaze M, Tsujioka K, Ishida Y, Fukunami M, Nakajima S, Kitabatake A and Abe H. Ejection timing as a major determinant of left ventricular relaxation rate in isolated perfused canine heart. Circulation research. 1984 ; 55 : 31-8.
 
240) Hori M, Inoue M, Kitakaze M, Tsujioka K, Ishida Y, Fukunami M, Nakajima S, Kitabatake A and Abe H. Loading sequence is a major determinant of afterload-dependent relaxation in intact canine heart. The American journal of physiology. 1985 ; 249 : H747-54.
 
241) Borlaug BA, Melenovsky V, Redfield MM, Kessler K, Chang HJ, Abraham TP and Kass DA. Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. Journal of the American College of Cardiology. 2007 ; 50 : 1570-7.
PubMed
242) Reyes M, Freeman GL, Escobedo D, Lee S, Steinhelper ME and Feldman MD. Enhancement of contractility with sustained afterload in the intact murine heart : blunting of length-dependent activation. Circulation. 2003 ; 107 : 2962-8.
PubMed
243) Verrier RL, Thompson PL and Lown B. Ventricular vulnerability during sympathetic stimulation : role of heart rate and blood pressure. Cardiovascular research. 1974 ; 8 : 602-10.
PubMed
244) Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC and Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. The New England journal of medicine. 1982 ; 307 : 205-11.
PubMed
245) Levy MN and Blattberg B. Effect of vagal stimulation on the overflow of norepinephrine into the coronary sinus during cardiac sympathetic nerve stimulation in the dog. Circulation research. 1976 ; 38 : 81-4.
PubMed
246) Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB and Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. The New England journal of medicine. 1984 ; 311 : 819-23.
PubMed
247) Kleiger RE, Miller JP, Bigger JT, Jr. and Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. The American journal of cardiology. 1987 ; 59 : 256-62.
PubMed
248) La Rovere MT, Bigger JT, Jr., Marcus FI, Mortara A and Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet (London, England). 1998 ; 351 : 478-84.
 
249) Bradley TD and Floras JS. Pathophysiologic and therapeutic implications of sleep apnea in congestive heart failure. Journal of cardiac failure. 1996 ; 2 : 223-40.
PubMed
250) Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC and Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 ; 373 : 2117-28.
PubMed
251) Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M and et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. The New England journal of medicine. 1991 ; 325 : 303-10.
 
252) Yusuf S, Pitt B, Davis CE, Hood WB, Jr. and Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The New England journal of medicine. 1992 ; 327 : 685-91.
PubMed
253) Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K and Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999 ; 100 : 2312-8.
 
254) Yusuf S, Sleight P, Pogue J, Bosch J, Davies R and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The New England journal of medicine. 2000 ; 342 : 145-53.
 
255) Opie LH. The new trials : AIRE, ISIS-4, and GISSI-3. Is the dossier on ACE inhibitors and myocardial infarction now complete? Cardiovascular drugs and therapy. 1994 ; 8 : 469-72.
PubMed
256) Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L and Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction : results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). New England Journal of Medicine. 1992 ; 327 : 678-84.
PubMed
257) Pilote L, Abrahamowicz M, Eisenberg M, Humphries K, Behlouli H and Tu JV. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ : Canadian Medical Association journal = journal de l 'Association medicale canadienne. 2008 ; 178 : 1303-11.
PubMed
258) Dahlof B, Hansson L, Lindholm L, Schersten B, Ekbom T and Wester P. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). The Lancet. 1991 ; 338 : 1281-5.
 
259) Scheen AJ. CAPPP trial. The Lancet. 1999 ; 353 : 1793-4.
 
260) Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S and Poole-Wilson PA. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study) : a randomised, double-blind trial. Lancet (London, England). 2009 ; 374 : 1840-8.
 
261) Dickstein K and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction : the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002 ; 360 : 752-60.
PubMed
262) Cohn JN. Improving outcomes in congestive heart failure : Val-HeFT. Cardiology. 1999 ; 91 : 19-22.
 
263) Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E and Califf R. Valsartan in acute myocardial infarction trial (VALIANT) : rationale and design. Am Heart J. 2000 ; 140 : 727-50.
PubMed
264) Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, Makita N, Iwanaga K, Zhu W, Kudoh S, Toko H, Tamura K, Kihara M, Nagai T, Fukamizu A, Umemura S, Iiri T, Fujita T and Komuro I. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol. 2004 ; 6 : 499-506.
PubMed
265) Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX and Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension. 2004 ; 43 : 1003-10.
 
266) Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA and Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004 ; 43 : 993-1002.
PubMed
267) Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z and Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 ; 345 : 861-9.
PubMed
268) Viberti G and Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus : a blood pressure-independent effect. Circulation. 2002 ; 106 : 672-8.
PubMed
269) Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England journal of medicine. 1999 ; 341 : 709-17.
PubMed
270) Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J and Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England journal of medicine. 2003 ; 348 : 1309-21.
PubMed
271) Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ and Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. The New England journal of medicine. 2011 ; 364 : 11-21.
PubMed
272) Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F and Pitt B. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function : analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Journal of the American College of Cardiology. 2013 ; 62 : 1585-93.
PubMed
273) Tsutsui H, Ito H, Kitakaze M, Komuro I, Murohara T, Izumi T, Sunagawa K, Yasumura Y, Yano M, Yamamoto K, Yoshikawa T, Tsutamoto T, Zhang J, Okayama A, Ichikawa Y, Kanmuri K and Matsuzaki M. Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF). Circulation journal : official journal of the Japanese Circulation Society. 2017 ; 82 : 148-58.
PubMed
274) Asakura M, Yamamoto H, Asai K, Hanatani A, Hirata K, Hirayakma A, Kimura K, Kobayashi Y, Momomura S, Nakagawa Y, Nishi Y, Saito Y, Satoh Y, Yamada T, Yamashina A, Yasuda S, Yoshikawa T, Kada A, Uesaka H and Kitakaze M. Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER). Cardiovascular drugs and therapy. 2015 ; 29 : 179-85.
PubMed
275) Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, Katus HA, Fowler MB and Packer M. Effects of initiating carvedilol in patients with severe chronic heart failure : results from the COPERNICUS Study. Jama. 2003 ; 289 : 712-8.
PubMed
276) Gottlieb SS, McCarter RJ and Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. The New England journal of medicine. 1998 ; 339 : 489-97.
PubMed
277) 中村健一. 研究倫理と臨床研究法. 肺癌. 2018 ; 58 : 944-47.
 
278) Silver MA, Horton DP, Ghali JK and Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. Journal of the American College of Cardiology. 2002 ; 39 : 798-803.
PubMed
279) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure : a randomized controlled trial. Jama. 2002 ; 287 : 1531-40.
PubMed
280) Sackner-Bernstein JD, Kowalski M, Fox M and Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure : a pooled analysis of randomized controlled trials. Jama. 2005 ; 293 : 1900-5.
PubMed
281) O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF, Jr., Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F and Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. The New England journal of medicine. 2011 ; 365 : 32-43.
 
282) Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, Yokoyama H, Tanaka K, Mizuno K, Nejima J and Kinoshita M. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure : the PROTECT multicenter randomized controlled study. Circulation journal : official journal of the Japanese Circulation Society. 2008 ; 72 : 1787-93.
 
283) Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H and Kitamura S. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND) : two randomised trials. Lancet (London, England). 2007 ; 370 : 1483-93.
 
284) Asanuma H, Sanada S, Asakura M, Asano Y, Kim J, Shinozaki Y, Mori H, Minamino T, Takashima S and Kitakaze M. Carperitide induces coronary vasodilation and limits infarct size in canine ischemic hearts : role of NO. Hypertension research : official journal of the Japanese Society of Hypertension. 2014 ; 37 : 716-23.
PubMed
285) Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, Okazaki H, Asai M, Nagamachi Y, Maeda N, Shintani Y, Minamino T, Asakura M, Kishimoto I, Funahashi T, Tomoike H and Kitakaze M. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. Journal of the American College of Cardiology. 2009 ; 53 : 2070-7.
PubMed
286) Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Dungen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC and Lefkowitz MP. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. The New England journal of medicine. 2019 ; 381 : 1609-20.
PubMed
287) Kaku K, Lee J, Mattheus M, Kaspers S, George J and Woerle HJ. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease-Results From EMPA-REG OUTCOMER. Circulation journal : official journal of the Japanese Circulation Society. 2017 ; 81 : 227-34.
 
288) Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Johansen OE and Inzucchi SE. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOMER trial. Eur Heart J. 2018 ; 39 : 363-370.
 
289) Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC and Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 ; 375 : 323-34.
PubMed
290) Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M and Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 ; 377 : 644-57.
PubMed
291) Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM and Sabatine MS. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018.
 
292) Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH and Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes : a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018.
PubMed
293) Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Vinh PN, Schou M, Tereshchenko S, Kober L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS and McMurray JJV. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Jama. 2020 ; 323 : 1353-68.
PubMed
294) Lytvyn Y, Skrtic M, Yang GK, Yip PM, Perkins BA and Cherney DZ. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. American journal of physiology Renal physiology. 2015 ; 308 : F77-83.
PubMed
295) Baartscheer A, Schumacher CA, Wust RC, Fiolet JW, Stienen GJ, Coronel R and Zuurbier CJ. Empagliflozin decreases myocardial cytoplasmic Na (+) through inhibition of the cardiac Na (+)/H (+) exchanger in rats and rabbits. Diabetologia. 2017 ; 60 : 568-73.
PubMed
296) Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA and Cherney DZI. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure : Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017 ; 136 : 1643-58.
PubMed
297) Yoshihara F, Imazu M, Hamasaki T, Anzai T, Yasuda S, Ito S, Yamamoto H, Hashimura K, Yasumura Y, Mori K, Watanabe M, Asakura M and Kitakaze M. An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER). Cardiovasc Drugs Ther. 2018.
PubMed
298) Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H and Wikstrand J. Rosuvastatin in older patients with systolic heart failure. The New England journal of medicine. 2007 ; 357 : 2248-61.
PubMed
299) Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M and Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial) : a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2008 ; 372 : 1231-9.
 
300) Takano H, Mizuma H, Kuwabara Y, Sato Y, Shindo S, Kotooka N, Fujimatsu D, Kobayashi Y, Inoue T, Node K and Komuro I. Effects of pitavastatin in Japanese patients with chronic heart failure : the Pitavastatin Heart Failure Study (PEARL Study). Circulation journal : official journal of the Japanese Circulation Society. 2013 ; 77 : 917-25.
 
301) Gheorghiade M, Konstam MA, Burnett JC, Jr., Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C and Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : the EVEREST Clinical Status Trials. Jama. 2007 ; 297 : 1332-43.
PubMed
302) Konstam MA, Gheorghiade M, Burnett JC, Jr., Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C and Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST Outcome Trial. Jama. 2007 ; 297 : 1319-31.
PubMed
303) Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L and Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. The New England journal of medicine. 2005 ; 352 : 1539-49.
PubMed
304) Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW and Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. The New England journal of medicine. 2004 ; 350 : 2140-50.
PubMed
305) Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS and Rouleau JL. Cardiac-resynchronization therapy for mild-to-moderate heart failure. The New England journal of medicine. 2010 ; 363 : 2385-95.
PubMed
306) Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA, 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D and Zareba W. Cardiac-resynchronization therapy for the prevention of heart-failure events. The New England journal of medicine. 2009 ; 361 : 1329-38.
PubMed
307) Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S and Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. Journal of the American College of Cardiology. 2008 ; 52 : 1834-43.
PubMed
308) Beshai JF, Grimm RA, Nagueh SF, Baker JH, 2nd, Beau SL, Greenberg SM, Pires LA and Tchou PJ. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. The New England journal of medicine. 2007 ; 357 : 2461-71.
PubMed
309) Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, Abraham WT, Ghio S, Leclercq C, Bax JJ, Yu CM, Gorcsan J, 3rd, St John Sutton M, De Sutter J and Murillo J. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation. 2008 ; 117 : 2608-16.
PubMed
310) Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC and Poirier VL. Long-term use of a left ventricular assist device for end-stage heart failure. The New England journal of medicine. 2001 ; 345 : 1435-43.
PubMed
311) Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM, 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ and Frazier OH. Advanced heart failure treated with continuous-flow left ventricular assist device. The New England journal of medicine. 2009 ; 361 : 2241-51.
PubMed
312) Belardinelli R, Georgiou D, Cianci G and Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure : effects on functional capacity, quality of life, and clinical outcome. Circulation. 1999 ; 99 : 1173-82.
PubMed
313) O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F and Pina IL. Efficacy and safety of exercise training in patients with chronic heart failure : HF-ACTION randomized controlled trial. Jama. 2009 ; 301 : 1439-50.
 
314) Hirsch AT, Talsness CE, Schunkert H, Paul M and Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circulation research. 1991 ; 69 : 475-82.
PubMed
315) Baker KM and Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. The American journal of physiology. 1990 ; 259 : H610-8.
PubMed
316) Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, Spirito P, Matsumori A, Moravec CS, Seidman JG and et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. The New England journal of medicine. 1995 ; 332 : 1058-64.
 
317) Mirza M, Marston S, Willott R, Ashley C, Mogensen J, McKenna W, Robinson P, Redwood C and Watkins H. Dilated cardiomyopathy mutations in three thin filament regulatory proteins result in a common functional phenotype. The Journal of biological chemistry. 2005 ; 280 : 28498-506.
 
318) Watkins H, Anan R, Coviello DA, Spirito P, Seidman JG and Seidman CE. A de novo mutation in alpha-tropomyosin that causes hypertrophic cardiomyopathy. Circulation. 1995 ; 91 : 2302-5.
 
319) Nakajima-Taniguchi C, Matsui H, Nagata S, Kishimoto T and Yamauchi-Takihara K. Novel missense mutation in alpha-tropomyosin gene found in Japanese patients with hypertrophic cardiomyopathy. Journal of molecular and cellular cardiolog y. 1995 ; 27 : 2053-8.
 
320) Watkins H, Conner D, Thierfelder L, Jarcho JA, MacRae C, McKenna WJ, Maron BJ, Seidman JG and Seidman CE. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nature genetics. 1995 ; 11 : 434-7.
PubMed
321) Anan R, Nakagawa M, Miyata M, Higuchi I, Nakao S, Suehara M, Osame M and Tanaka H. Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation. 1995 ; 91 : 955-61.
 
322) Ahn AH and Kunkel LM. The structural and functional diversity of dystrophin. Nature genetics. 1993 ; 3 : 283-91.
PubMed
323) Barrans JD, Allen PD, Stamatiou D, Dzau VJ and Liew CC. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. The American journal of pathology. 2002 ; 160 : 2035-43.
PubMed
324) Tan FL, Moravec CS, Li J, Apperson-Hansen C, McCarthy PM, Young JB and Bond M. The gene expression fingerprint of human heart failure. Proceedings of the National Academy of Sciences of the United States of America. 2002 ; 99 : 11387-92.
PubMed
325) Min KD, Asakura M, Liao Y, Nakamaru K, Okazaki H, Takahashi T, Fujimoto K, Ito S, Takahashi A, Asanuma H, Yamazaki S, Minamino T, Sanada S, Seguchi O, Nakano A, Ando Y, Otsuka T, Furukawa H, Isomura T, Takashima S, Mochizuki N and Kitakaze M. Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochemical and biophysical research communications. 2010 ; 393 : 55-60.
PubMed
326) Asakura M, Asanuma H, Kim J, Liao Y, Nakamaru K, Fujita M, Komamura K, Isomura T, Furukawa H, Tomoike H and Kitakaze M. Impact of adenosine receptor signaling and metabolism on pathophysiology in patients with chronic heart failure. Hypertension research : official journal of the Japanese Society of Hypertension. 2007 ; 30 : 781-7.
PubMed
327) Liao Y, Takashima S, Asano Y, Asakura M, Ogai A, Shintani Y, Minamino T, Asanuma H, Sanada S, Kim J, Ogita H, Tomoike H, Hori M and Kitakaze M. Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circulation research. 2003 ; 93 : 759-66.
PubMed
328) Fujita M, Asakura M, Sanada S, Funaya H, Tsukamoto O, Komamura K, Asanuma H, Taketani S, Isomura T, Nakamaru K, Furukawa H, Sawa Y, Hori M and Kitakaze M. Activation of ecto-5'-nucleotidase in the blood and hearts of patients with chronic heart failure. Journal of cardiac failure. 2008 ; 14 : 426-30.
PubMed
329) Kitakaze M, Asakura M, Sakata Y, Asanuma H, Sanada S, Kuzuya T, Miyazaki J, Takashima S and Hori M. cDNA array hybridization reveals cardiac gene expression in acute ischemic murine hearts. Cardiovascular drugs and therapy. 2001 ; 15 : 125-30.
PubMed
330) Asakura M, Kitakaze M, Sakata Y, Asanuma H, Sanada S, Kim J, Ogida H, Liao Y, Node K, Takashima S, Tada M and Hori M. Adenosine-induced cardiac gene expression of ischemic murine hearts revealed by cDNA array hybridization. Circulation journal : official journal of the Japanese Circulation Society. 2002 ; 66 : 93-6.
PubMed
331) Asakura M, Takashima S, Asano Y, Honma T, Asanuma H, Sanada S, Shintani Y, Liao Y, Kim J, Ogita H, Node K, Minamino T, Yorikane R, Agai A, Kitamura S, Tomoike H, Hori M and Kitakaze M. Canine DNA array as a potential tool for combining physiology and molecular biology. Circulation journal : official journal of the Japanese Circulation Society. 2003 ; 67 : 788-92.
PubMed
332) Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, Miyado K, Adachi S, Kitakaze M, Hashimoto K, Raab G, Nanba D, Higashiyama S, Hori M, Klagsbrun M and Mekada E. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proceedings of the National Academy of Sciences of the United States of America. 2003 ; 100 : 3221-6.
PubMed
333) Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M and Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF : metalloproteinase inhibitors as a new therapy. Nature medicine. 2002 ; 8 : 35-40.
PubMed
334) Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL and Packer M. The Seattle Heart Failure Model : prediction of survival in heart failure. Circulation. 2006 ; 113 : 1424-33.
PubMed
335) Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JG, Carson PE, Maggioni AP, Mann DL, Pitt B, Poole-Wilson PA and Levy WC. Prediction of mode of death in heart failure : the Seattle Heart Failure Model. Circulation. 2007 ; 116 : 392-8.
 
336) Sartipy U, Dahlstrom U, Edner M and Lund LH. Predicting survival in heart failure : validation of the MAGGIC heart failure risk score in 51,043 patients from the Swedish heart failure registry. European journal of heart failure. 2014 ; 16 : 173-9.
PubMed
337) Rahimi K, Bennett D, Conrad N, Williams TM, Basu J, Dwight J, Woodward M, Patel A, McMurray J and MacMahon S. Risk prediction in patients with heart failure : a systematic review and analysis. JACC Heart failure. 2014 ; 2 : 440-6.
PubMed
338) Yoshida A, Asakura M, Asanuma H, Ishii A, Hasegawa T, Minamino T, Takashima S, Kanzaki H, Washio T and Kitakaze M. Derivation of a mathematical expression for predicting the time to cardiac events in patients with heart failure : a retrospective clinical study. Hypertension research : official journal of the Japanese Society of Hypertension. 2013 ; 36 : 450-6.
PubMed
339) Sakamoto M, Fukuda H, Kim J, Ide T, Kinugawa S, Fukushima A, Tsutsui H, Ishii A, Ito S, Asanuma H, Asakura M, Washio T and Kitakaze M. The impact of creating mathematical formula to predict cardiovascular events in patients with heart failure. Scientific reports. 2018 ; 8 : 3986.
PubMed
340) Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S and Pfeffer MA. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction : results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology. 2006 ; 47 : 1997-2004.
PubMed
341) Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW and Andrews mL. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England journal of medicine. 2002 ; 346 : 877-83.
PubMed
342) Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM and Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. The New England journal of medicine. 2005 ; 352 : 225-37.
PubMed
343) Ishiyama Y, Hoshide S, Mizuno H and Kario K. Constipation-induced pressor effects as triggers for cardiovascular events. Journal of clinical hypertension (Greenwich, Conn). 2019 ; 21 : 421-5.
 
344) Honkura K, Tomata Y, Sugiyama K, Kaiho Y, Watanabe T, Zhang S, Sugawara Y and Tsuji I. Defecation frequency and cardiovascular disease mortality in Japan : The Ohsaki cohort study. Atherosclerosis. 2016 ; 246 : 251-6.
PubMed
345) Laugsand LE, Strand LB, Platou C, Vatten LJ and Janszky I. Insomnia and the risk of incident heart failure : a population study. European heart journal. 2014 ; 35 : 1382-93.
PubMed
346) Dunlay SM, Roger VL, Weston SA, Bangerter LR, Killian JM and Griffin JM. Patient and Spousal Health and Outcomes in Heart Failure. Circulation Heart failure. 2017 ; 10.
PubMed
347) Zhaowei Z, Xiaofan P, Hebin X, Cuihong T, Haoran X, Qinna L, Zhenzhen L, Xinqun H, Zhenfei F, Jianjun T, Yanshu Z, Hong Y, Chun S, Shi T, Qiming L, Hejun J, Xiaoling L and Shenghua Z. Comparison of One-Year Survival After Acute Coronary Syndrome in Patients > 75 Years of Age With Versus Without Living With Spouse. The American journal of cardiology. 2019 ; 123 : 1-6.
PubMed
348) Cole GD, Patel SJ, Zaman N, Barron AJ, Raphael CE, Mayet J and Francis DP. "Triple therapy" of heart failure with angiotensin-converting enzyme inhibitor, beta-blocker, and aldosterone antagonist may triple survival time : shouldn't we tell patients? JACC Heart failure. 2014 ; 2 : 545-8.
 
349) Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T and Kinoshita M. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. Journal of the American College of Cardiology. 2000 ; 36 : 1587-93.
PubMed
350) Fukuda H, Suwa H, Nakano A, Sakamoto M, Imazu M, Hasegawa T, Takahama H, Amaki M, Kanzaki H, Anzai T, Mochizuki N, Ishii A, Asanuma H, Asakura M, Washio T and Kitakaze M. Non-linear Equation using Plasma Brain Natriuretic Peptide Levels to Predict Cardiovascular Outcomes in Patients with Heart Failure. Scientific reports. 2016 ; 6 : 37073.
PubMed
351) Handbook of data mining and knowledge discovery. 2002 : 980.
 
352) Washio T, Takashi W, 大阪大学産業科学研究所, The Institute of S and Industrial Research OU. Editor's Introduction to "Data Mining and Statistical Science" (<Special Issue> Data Mining and Statistical Science). 人工知能学会誌 = Journal of Japanese Society for Artificial Intelligence. 2007 ; 22 : 272.
 
353) 鷲尾隆. データマイニングとは何か? -代表的基礎技術. 日本ソフトウェア科学会データマイニング技術講座資料, Sept 2009. 2009 : 1-25.
 
354) Kitakaze M, Asakura M, Nakano A, Takashima S and Washio T. Data Mining as a Powerful Tool for Creating Novel Drugs in Cardiovascular Medicine : The Importance of a "Back-and-Forth Loop" Between Clinical Data and Basic Research. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy. 2015 ; 29 : 309-15.
 
355) Kim J, Washio T, Yamagishi M, Yasumura Y, Nakatani S, Hashimura K, Hanatani A, Komamura K, Miyatake K, Kitamura S, Tomoike H and Kitakaze M. A novel data mining approach to the identification of effective drugs or combinations for targeted endpoints--application to chronic heart failure as a new form of evidence-based medicine. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy. 2004 ; 18 : 483-9.
 
356) Terada A, Okada-Hatakeyama M, Tsuda K and Sese J. Statistical significance of combinatorial regulations. Proceedings of the National Academy of Sciences of the United States of America. 2013 ; 110 : 12996-3001.
PubMed
357) Asakura M, Kim J, Asanuma H, Hamasaki T, Tsukahara K, Higashino Y, Ishikawa T, Nakama Y, Koba S, Maruyama Y, Tsujimoto M, Himeno H, Ohkusa T, Fujino S, Shimizu M, Endo T, Yoda S, Muroya T, Murohara T, Ohte N, Suzuki H, Kohno T, Fukui K, Shiono T, Takase H, Uzui H, Nagai Y, Hashimoto Y, Ikeda S, Mizuno S, Tamita K, Fujita M, Satake K, Kinoshita Y, Nunohiro T, Sakagami S, Higaki J, Morii I, Sawada R, Hiasa Y, Shigemasa T, Nakahama M, Sata M, Doi O, Ueda T, Yamada T, Yamanouchi T, Yamaguchi H, Morita Y, Hayashi H and Kitakaze M. Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction? Cardiovascular drugs and therapy. 2017 ; 31 : 401-11.
PubMed

書評

最近チェックした商品履歴

Loading...